• Digital Media
  • TSN News
  • Trial Watch
  • Site Watch
  • Investor Watch
  • Pharma Watch
  • Price Watch
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

BeyondSpring to Host Second-Quarter 2020 Financial Results and Operational Update Conference Call on September 3rd, 2020

Aug 27, 2020 | Globe News Wire

NEW YORK, Aug. 27, 2020 (GLOBE NEWSWIRE) — BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report its second-quarter 2020 financial results and host an operational update conference call on Thursday, September 3rd, 2020, at 8 a.m. Eastern Time.

The conference call may be accessed by dialing 1-877-451-6152 (U.S.) or 1-201-389-0879 (international) and referencing conference ID: 13709037. A live webcast will be available on BeyondSpring’s website at www.beyondspringpharma.com under “Events & Presentations” in the Investors section. An archived replay of the webcast will be available for 30 days.

About BeyondSpring
Headquartered in New York, BeyondSpring is a global, clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients with high unmet medical needs. BeyondSpring’s first-in-class lead immune asset, Plinabulin, is a potent antigen-presenting cell (APC) inducer. It is currently in two Phase 3 clinical trials for two severely unmet medical needs indications: one is for the prevention of chemotherapy-induced neutropenia (CIN), the most frequent cause for a chemotherapy regimen dose’s decrease, delay, downgrade or discontinuation, which can lead to suboptimal clinical outcomes. The other is for non-small cell lung cancer (NSCLC) treatment in EGFR wild-type patients. As a “pipeline drug,” Plinabulin is in various I/O combination studies to boost PD-1 / PD-L1 antibody anti-cancer effects. In addition to Plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a drug discovery platform dubbed “molecular glue” that uses the protein degradation pathway.

Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements that are not historical facts. Words such as “will,” “expect,” “anticipate,” “plan,” “believe,” “design,” “may,” “future,” “estimate,” “predict,” “objective,” “goal,” or variations thereof and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are based on BeyondSpring’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, difficulties raising the anticipated amount needed to finance the Company’s future operations on terms acceptable to the Company, if at all, unexpected results of clinical trials, delays or denial in regulatory approval process, results that do not meet our expectations regarding the potential safety, the ultimate efficacy or clinical utility of our product candidates, increased competition in the market, and other risks described in BeyondSpring’s most recent Form 20-F on file with the U.S. Securities and Exchange Commission. All forward-looking statements made herein speak only as of the date of this release and BeyondSpring undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Contacts
Scott Eckstein / Caitlin Kasunich
KCSA Strategic Communications
212.896.1210 / 212.896.1241
seckstein @kcsa.com / [email protected]

  • Facebook
  • Twitter
  • LinkedIn

0 Comments

Popular Posts

Dr. Solomon Talks PXT3003 Taking On Charcot Marie-Tooth Disease | Podcast

Dr. Solomon Talks PXT3003 Taking On Charcot Marie-Tooth Disease | Podcast

Dr Lenze of Washington University St. Louis Talks Antidepressant Fluvoxamine Covid-19 Clinical Trial | Podcast

Dr Lenze of Washington University St. Louis Talks Antidepressant Fluvoxamine Covid-19 Clinical Trial | Podcast

Dr. Ragan Discusses X4’s Work To Advance Disease-Modifying Therapies For Rare Genetic Diseases | Podcast

Dr. Ragan Discusses X4’s Work To Advance Disease-Modifying Therapies For Rare Genetic Diseases | Podcast

Dr. CJ Barnum of INmune Bio | NIH Grant tests Neuroinflammation on Treatment Resistent Depression

Dr. CJ Barnum of INmune Bio | NIH Grant tests Neuroinflammation on Treatment Resistent Depression

Hartmut Ehrlich and Philippe Pouletty discuss Abivax Clinical Programs Involving Covid-19 and more.

Hartmut Ehrlich and Philippe Pouletty discuss Abivax Clinical Programs Involving Covid-19 and more.

Dr. Negin Hajizadeh: Researchers Finding A Very Effective Treatment For Covid-19 In New Study

Dr. Negin Hajizadeh: Researchers Finding A Very Effective Treatment For Covid-19 In New Study

Subscribe: Newsletter
Subscribe: YouTube
Subscribe: Podcast

Advertise with us today!

24/7 News Feed

ERYTECH Announces Conference Webcast to Discuss Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia to be Presented at the American Society of Hematology 2020 Annual Meeting

Pandion Therapeutics Appoints Katina Dorton to its Board of Directors

Osmotica Pharmaceuticals plc Announces Agreement to Settle Patent Litigation with Adamas

Adamas Announces Agreement to Amend Royalty-Backed Loan Agreement with HealthCare Royalty Partners

Adamas Announces Agreement to Settle Patent Litigation with Osmotica

Roche announces FDA approval of Gavreto (pralsetinib) for people with advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers

See More

159 W Broadway, Suite 200
Salt Lake City, UT 84101

[email protected]

Popular Links

Contact Us
Digital Media
Blog
Privacy Policy
Terms Of Use
Advertise With Us

Connect With Us

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.
Copyright © TrialSite News. All Rights Reserved.

Pin It on Pinterest

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site you consent to our use of cookies.Ok